What is ProSomnus Price-to-Operating-Cash-Flow?
As of today (2024-05-31), ProSomnus's share price is $0.028.
ProSomnus's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.79. Hence, ProSomnus's Price-to-Operating-Cash-Flow Ratio for today is .
The historical rank and industry rank for ProSomnus's Price-to-Operating-Cash-Flow or its related term are showing as below:
ProSomnus's Cash Flow from Operations per share for the
three
months ended in Mar. 2024 was $-0.04.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.79.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -61.70% per year.
During the past 4 years, ProSomnus's highest 3-Year average Operating Cash Flow per Share Growth Rate was -61.70% per year. The lowest was -61.70% per year. And the median was -61.70% per year.
ProSomnus Price-to-Operating-Cash-Flow Historical Data
The historical data trend for ProSomnus's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ProSomnus Price-to-Operating-Cash-Flow Chart
|
ProSomnus Annual Data
|
|
Trend |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Price-to-Operating-Cash-Flow |
|
- |
- |
- |
- |
|
ProSomnus Quarterly Data
|
|
Dec20 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Price-to-Operating-Cash-Flow |
Get a 7-Day Free Trial
|
|
|
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison of ProSomnus's Price-to-Operating-Cash-Flow
For the Medical Devices subindustry, ProSomnus's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ProSomnus's Price-to-Operating-Cash-Flow Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ProSomnus's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where ProSomnus's Price-to-Operating-Cash-Flow falls into.
ProSomnus Price-to-Operating-Cash-Flow Calculation
ProSomnus's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 0.028 | / | -0.793 |
| = | |
ProSomnus's Share Price of today is $0.028.
ProSomnus's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.79.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
ProSomnus (ProSomnus) Business Description
Traded in Other Exchanges
N/A
Address
5675 Gibraltar Drive, Pleasanton, CA, USA, 94588
ProSomnus Inc is a medical device manufacturer. It manufacturers precision, mass-customized oral appliance therapy devices to treat obstructive sleep apnea, which affects over 74 million Americans and is associated with serious comorbidities, including heart failure, stroke, hypertension, morbid obesity and type 2 diabetes. ProSomnus's patented devices are more comfortable and less invasive alternative to continuous positive airway pressure therapy, and lead to more effective and patient-preferred outcomes.
Executives
| Sung Kim |
officer: Chief Technical Officer |
5675 GIBRALTAR AVENUE, PLEASANTON CA 94588 |
| John Steffens |
10 percent owner |
C/O DIGITALBRIDGE GROUP, INC., 750 PARK OF COMMERCE DRIVE SUITE 210, BOCCA RATON FL 33487 |
| Gregory P. Ho |
10 percent owner |
C/O SPRING MOUNTAIN CAPITAL, LP, 650 MADISON AVENUE, 20TH FLOOR, NEW YORK NY 10022 |
| Brian B Dow |
officer: Chief Financial Officer |
5675 GIBRALTAR AVENUE, PLEASANTON CA 94588 |
| Smc Holdings Ii, Lp |
10 percent owner |
65 EAST 55TH STREET, 33RD FLOOR, NEW YORK NY 10022 |
| Smc Holdings Ii G.p., Llc |
10 percent owner |
C/O SPRING MOUNTAIN CAPITAL, LP, 650 MADISON AVENUE, 20TH FLOOR, NEW YORK NY 10022 |
| Laing Rikkers |
director |
5675 GIBRALTAR AVENUE, PLEASANTON CA 94588 |
| Len Liptak |
director, officer: Chief Executive Officer |
5675 GIBRALTAR AVENUE, PLEASANTON CA 94588 |
| Mark Thomas Murphy |
officer: Chief Growth Officer |
5675 GIBRALTAR AVENUE, PLEASANTON CA 94588 |
| Hgp Iii, Llc |
10 percent owner |
3708 ASHFORD PLACE, GREENVILLE NC 27858 |
| Steven Robert Pacelli |
director |
5555 OBERLIN DRIVE, SAN DIEGO CA 92121 |
| Hmc, Llc |
10 percent owner |
3708 ASHFORD PLACE, GREENVILLE NC 27858 |
| Healthpointcapital, Llc |
10 percent owner |
C/O HEALTHPOINTCAPITAL, 505 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022 |
| Healthpointcapital Partners Iii Lp |
10 percent owner |
505 Park Avenue, 12th Floor, New York NY 10022 |
| Leonard Hedge |
director |
7855 BELLA MONTANIA LANE, PALO CEDRO CA 96073 |
ProSomnus (ProSomnus) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OSAPQ has been successfully added to your